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Dear Editor,
Gaucher disease (GD) is a progressive, multisystem, autoso-
mal recessive lysosomal storage disorder caused by the defi-
cient activity of the lysosomal enzyme, glucocerebrosidase,
arising from mutations in the GBA1 gene (1q21) [1]. Hema-
tological symptoms, such as thrombocytopenia or splenomeg-
aly, are frequent disclosing signs of GD type 1 (GD1).
Here, we report the case of a young Iranian woman, orig-
inating from the city of Ahvaz in the southwest Iran
(Khuzestan Province) but living in Sweden since the age of
16 years. The ancestors of her both parents migrated to Iran
from Caucasus region in Georgia. Although the parents of the
patient had a consanguineous relationship (cousins), they
were not aware of any previous cases of GD in their family,
apart from their own children.
At the age of 4, the patient developed a huge belly, “as a
pregnant woman” according to the mother’s relation. She was
splenectomized 1 year later due to massive splenomegaly and
increased bleeding tendency (Fig. 1a). Histopathology of the
spleen disclosed the presence of storage histiocytes with
Gaucher cell morphology. However, further enzyme assay or
GBA1mutation analysis was not performed at that time. Later
on, the patient suffered periodically from a severe skeletal
pain, followed by the skeletal deformations in her right leg
and left arm (Fig. 1b, c).
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Noteworthy, the patient had four older siblings. Two oldest
brothers are healthy and alive. The third brother, 1 year older
than the patient, died at the age of 5 years, having at that time a
huge belly. He was never splenectomized. Postmortem exam-
ination revealed histopathology of GD. Her 6 years older sister
was splenectomized at the age of 5 due to massive spleno-
megaly and easy bruising. The spleen histopathology
disclosed a morphological picture of GD. After some time,
she started to experience severe skeletal pain accompanied by
increasing hepatomegaly and bleeding problems. The pa-
tient’s sister died at the age of 21 years, having a large
abdomen “as during late pregnancy,” due to a massive hepa-
tomegaly, according to the patient’s relation. None of the
affected siblings, including the patient, displayed any neuro-
logic symptoms. None of them was treated in Iran with
enzyme replacement therapy (ERT) either.
The patient’s mother, 1 year after the death of her second
child because of GD, decided to immigrate with her last daugh-
ter to Norway, in hope to allow the patient ERTand to avoid the
fate of older siblings with GD.However, the patient did not start
ERT in Norway, and she moved with her mother to Sweden.
The final diagnosis of GD was confirmed in Sweden by
disclosing Gaucher cells in the bone marrow (Fig. 1d–f) and
then reduced activity of glucocerebrosidase in peripheral
blood leukocytes (0.49 μkat/kg protein; normal range 2.1–
3.8) and increased activity of plasma chitotriosidase
(9,743 nkat/L; normal range <40). Further direct DNA se-
quencing of the coding exons and intron/exon borders in the
GBA1 gene revealed the heterozygous mutations c.798C>G
and c.1040T>G.
The mutation c.798C>G results in amino acid change from
phenylalanine to leucine at position 266 (p.Phe266Leu),
which has slightly different physicochemical properties than
phenylalanine. The mutation c.1040T>G results in the change
of the amino acid isoleucine at position 347 into serine
(pIle347Ser). There is a large physicochemical difference
Fig. 1 a A large scar after
splenectomy. b, c Primary skeletal
deformations of the right leg and
the left arm (marked red),
followed by the secondary
deformations of the spine and the
left feet (marked black). d Bone
marrow cytology; centrally
placed histiocyte with Gaucher
cell morphology (MGG stain). e, f
Bone marrow histology;
prominent histiocytic infiltrates
composed of Gaucher cells; iron-
hematoxylin stain (e) and HE
stain (f)
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between Ile and Ser. Both phenylalanine at position 266 and
isoleucine at position 347 are highly conserved between spe-
cies (up toCaenorhabditis elegans). To the best of our knowl-
edge, both aforementioned mutations in the GBA1 were never
before reported in patients with GD.
The patient started ERTwith imiglucerase (Cerezyme™) at
the dose of 60 IU/kg at the age of 17 years. With time, she
responded very well to the ERT, experiencing normalization
of the liver size and her body weight as well as normalization
of the whole blood hemoglobin concentration and platelet
count. She has never again experienced acute skeletal pain.
Nevertheless, she experiences from time to time pain related
to her persistent skeletal deformities. When on ERT, she was
able to begin studies, gain a profession, and find a job.
Currently, the patient is almost 26 years old and clinically
stable. Thanks to ERT, which she has been receiving for
9 years now, she lives an almost normal life.
The onset of GD in early childhood, an aggressive course
in respect to visceral, hematologic, and skeletal domains of
GD, as well as the lack of neurologic symptoms indicate a
severe form of GD1 in the reported patient and her two
deceased siblings. Importantly, the present case illustrates a
striking ability of ERT to reverse an uniformly lethal outcome
of GD caused by the novel heterozygous mutations
c.798C>G/c.1040T>G in the GBA1.
Although GD is particularly prevalent among Ashkenazi
Jews, it can be found in all ethnic groups [1]. The clinical
presentation of GD is highly variable [2–4], and in the absence
of a known affected family member, GD1 remains a diagnos-
tic challenge and is often not included in differential diagnosis
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of thrombocytopenia even by experienced hematologists [5].
A suspicion of GD based on morphological findings, such as
the presence of Gaucher cells in any tissue sample, should
always be confirmed by enzymatic and genetic assays [1].
Finally, this family story is an obvious reminder that ERT does
save lives in GD.
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Informed consent was obtained from the patient included in this case
report.
